CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.2.2.1 Competitive intelligence of companies and their strategies
3.3 Porters five forces analysis
3.3.1 Bargaining power of the suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Competitive rivalry
3.3.5 Threat of substitutes
3.4 Market share analysis, 2015
3.5 Market dynamics
3.5.1 Drivers
3.5.1.1 Prevalence of hypertension
3.5.1.2 Changing lifestyle of people
3.5.1.3 Improvement of healthcare infrastructure in developing countries
3.5.1.4 Cost effectiveness of the procedure
3.5.2 Restraints
3.5.2.1 Painful procedure
3.5.2.2 Stringent approval process for renal denervation devices
3.5.3 Opportunities
3.5.3.1 Applications of renal denervation in other diseases
3.5.3.2 Clinical Trials
3.6 Clinical trials
3.6.1 The Symplicity clinical trial program
3.6.1.1 SYMPLICITY HTN-1
3.6.1.2 SYMPLICITY HTN-2
3.6.1.3 SYMPLICITY HTN-3
3.6.1.4 Global SYMPLICITY Registry
3.6.1.5 SYMPLICITY-HF
3.6.1.6 Symplicity Spyral(TM) Catheter Feasibility Study
3.6.1.7 HTN-Japan
3.6.1.8 SYMPLICITY HTN-India
3.6.2 Clinical trials for EnligHTN renal denervation system
3.6.2.1 EnligHTN I Trial
3.6.2.2 EnligHTN II Trial
3.6.2.3 EnligHTN III Trial
3.6.2.4 EnligHTN IV Trial
3.6.2.5 EnligHTNment Trial
3.6.3 Other clinical trials
CHAPTER 4 WORLD RENAL DENERVATION MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Symplicity
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Vessix (V2)
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 EnligHTN
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.5 Paradise
4.5.1 Key market trends
4.5.2 Key growth factors and opportunities
4.5.3 Market size and forecast
4.6 Iberis
4.6.1 Key market trends
4.6.2 Key growth factors and opportunities
4.6.3 Market size and forecast
4.7 Others
4.7.1 Key market trends
4.7.2 Key growth factors and opportunities
4.7.3 Market size and forecast
CHAPTER 5 WORLD RENAL DENERVATION MARKET, BY TECHNOLOGY
5.1 Overview
5.1.1 Market size and forecast
5.2 Radiofrequency
5.2.1 Market size and forecast
5.3 Ultrasound
5.3.1 Market size and forecast
5.4 Micro-infusion
5.4.1 Market size and forecast
CHAPTER 6 WORLD RENAL DENERVATION MARKET, BY GEOGRAPHY, 2014-2022
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 U.S. market size and forecast
6.2.5 Canada market size and forecast
6.2.6 Mexico market size and forecast
6.3 Europe
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.3.4 Germany market size and forecast
6.3.5 France market size and forecast
6.3.6 U.K. market size and forecast
6.3.7 Italy market size and forecast
6.3.8 Spain market size and forecast
6.3.9 Rest of Europe market size and forecast
6.4 Asia-Pacific
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Japan market size and forecast
6.4.5 China market size and forecast
6.4.6 India market size and forecast
6.4.7 Australia market size and forecast
6.4.8 New Zealand market size and forecast
6.4.9 Others market size and forecast
6.5 LAMEA
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.5.4 Brazil market size and forecast
6.5.5 South Africa market size and forecast
6.5.6 Saudi Arabia market size and forecast
6.5.7 Rest of LAMEA market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1 Ablative Solutions, Inc.
7.1.1 Company Overview
7.1.2 Company Snapshot
7.1.3 Operating Business Segments
7.1.4 Key Strategic Moves & Developments
7.2 Boston Scientific Corporation
7.2.1 Company Overview
7.2.2 Operating Business Segments
7.2.3 Business Performance
7.2.4 Key Strategic Moves & Developments
7.3 Cardiosonic Ltd
7.3.1 Company Overview
7.3.2 Company Snapshot
7.3.3 Key Strategic Moves & Developments
7.4 Kona Medical, Inc.
7.4.1 Company Overview
7.4.2 Company Snapshot
7.4.3 Key Strategic Moves & Developments
7.5 Medtronic plc
7.5.1 Company Overview
7.5.2 Company Snapshot
7.5.3 Operating Business Segments
7.5.4 Business Performance
7.5.5 Key Strategic Moves & Developments
7.6 Mercator MedSystems, Inc.
7.6.1 Company Overview
7.6.2 Company Snapshot
7.6.3 Operating Business Segments
7.6.4 Key Strategic Moves & Developments
7.7 ReCor Medical, Inc.
7.7.1 Company Overview
7.7.2 Company Snapshot
7.7.3 Key Strategic Moves & Developments
7.8 Renal Dynamics Limited
7.8.1 Company Overview
7.8.2 Company Snapshot
7.8.3 Key Strategic Moves & Developments
7.9 St. Jude Medical, Inc.
7.9.1 Company Overview
7.9.2 Operating Business Segments
7.9.3 Business Performance
7.9.4 Key Strategic Moves & Developments
7.10 Terumo Corporation
7.10.1 Company Overview
7.10.2 Company Snapshot
7.10.3 Operating Business Segments
7.10.4 Business Performance
7.10.5 Key Strategic Moves & Developments
